Atlas Trials

Tasly Biopharmaceuticals Co., Ltd.

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Tasly Biopharmaceuticals Co., Ltd.

RecordFirmDate
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD） (NCT07128797)Tasly Biopharmaceuticals Co., Ltd.2025-07-24
A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer (NCT06838546)Tasly Biopharmaceuticals Co., Ltd.2025-02-24
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors (NCT06724263)Tasly Biopharmaceuticals Co., Ltd.2024-12-01
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (NCT05700591)Tasly Biopharmaceuticals Co., Ltd.2023-01-29
A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors (NCT05650385)Tasly Biopharmaceuticals Co., Ltd.2022-12-01
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects (NCT05655221)Tasly Biopharmaceuticals Co., Ltd.2022-08-30
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (NCT03578822)Tasly Biopharmaceuticals Co., Ltd.2018-08-10
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) (NCT03541668)Tasly Biopharmaceuticals Co., Ltd.2018-05-18
A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (NCT03108833)Tasly Biopharmaceuticals Co., Ltd.2017-06-06

Track Tasly Biopharmaceuticals Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.